There is no benefit to adding palbociclib to endocrine therapy in patients with early hormone receptor (HR)-positive, HER2-negative breast cancer, according to final results from the phase 3 PALLAS trial.
The results are surprising because cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy is the standard of care for advanced breast cancer.
PALLAS (Palbociclib Collaborative Adjuvant Study) is a randomized, phase 3, open-label trial in which 5,761 patients from 21